Therapeutical combination against cancer

Details Therapeutical combination against cancer Therapeutical combination against cancer

2006-07-04

2006-07-04

Siew, Jeffrey (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S143100, C424S180100, C424S181100, C514S054000, C514S061000

Reexamination Certificate

active

07070778

ABSTRACT:
The present invention relates to compositions and methods for treating humans and warm-blood animals suffering from cancer. More particularly, a therapeutical treatment in which a monoclonal antibody is administered with either β-(1,3)-glucan like laminarin or a oligo-β-(1,3)-glucan and a pharmaceutically acceptable carrier, to patients suffering from cancer are described.

REFERENCES:
patent: 6632940 (2003-10-01), Yvin et al.
patent: 2003/0045706 (2003-03-01), Yvin et al.
patent: WO 98/39013 (1998-09-01), None
patent: WO 02/05871 (2002-08-01), None
patent: WO 03-045414 (2003-06-01), None
Bohn et al. (Carbohydrate Polymers, 28, Mar. 14, 1995).
Gura (Science, v278, 1997, pp. 1041-1042).
Tschmelitsch et al. (Canc. Res., 1997, vol. 57, No. 11, abstract).
Anishi et al., “Induction of TNF-α Production from Human Peripheral Blood Monocytes with β-1,3-Glucan Oligomer Prepared from Laminarin...”, Journal of Bioscience and BioEngineering, vol. 95, No. 2, pp. 192-195, 2003.

Affiliated with

Also associated with

Rating

Therapeutical combination against cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutical combination against cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutical combination against cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3570545